In a phase II trial, 16 patients with previously treated NSCLC harboring KRAS G12D mutation were treated with bortezomib, but results were disappointing: only 1 partial response was seen, mPFS was 1 month and mOS 13 months. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.